TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21845341

Group type: EXPERIMENTAL
Intervention: Strength Training (ST, N = 13, twice a week, 70‐90% 1‐RM)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Power Training (PT, N = 15, twice a week, 30‐50% 1‐RM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control (N = 11)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combined data for all groups
Number of subjects: 39
Study: 19303810

Group type: EXPERIMENTAL
Intervention: Low-intensity continuous Theta Burst Stimulation (cTBS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-intensity intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 9
Study: 17470434

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly)
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 16249836

Group type: EXPERIMENTAL
Intervention: 2 MP consumer color display
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 MP business color display
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 MP medical-grade gray display
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3 MP gray display
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All displays
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All users
Number of subjects: 9
Study: 12930498

Group type: EXPERIMENTAL
Intervention: Medium Overdrive (MO) pacing at 10-19 beats/min > mean heart rate
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High Overdrive (HO) pacing at 20-29 beats/min > mean heart rate
Number of subjects: 42

Group type: COMPARATOR
Intervention: No pacing (OAO mode)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: No difference between MO and HO pacing
Number of subjects: 42
Study: 10823594

Group type: EXPERIMENTAL
Intervention: Abduction splintage
Number of subjects: 44

Group type: COMPARATOR
Intervention: Observation (unsplinted group)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 44
Study: 8894937

Group type: EXPERIMENTAL
Intervention: d-sotalol (2 mg/kg IV in 15 min, followed by 1 mg/kg per hour)
Number of subjects: 15
Study: 2003079

Group type: EXPERIMENTAL
Intervention: Indirect blood pressure methods (bell and diaphragm components of the stethoscope)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Direct arterial method (radial intraarterial cannula)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Random-zero (RZ) sphygmomanometer for indirect blood pressure
Number of subjects: 30
Study: 6152120

Group type: EXPERIMENTAL
Intervention: Fansidar (1 tablet a week)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Chloroquine (300 mg weekly)
Number of subjects: 173
Study: 29059120

Group type: EXPERIMENTAL
Intervention: Daily Engagement in Meaningful Activity (DEMA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Information Support (Control)
Number of subjects: 40
Study: 25461390

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D (cholecalciferol) 4000 IU
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D (cholecalciferol) 8000 IU
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin D (4000 IU and 8000 IU) in vitamin D insufficient subjects (serum 25(OH)D<29 ng/mL)
Number of subjects: 46
Study: 22971719

Group type: COMPARATOR
Intervention: Two types of antiplatelet agents (Group I)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Single antiplatelet agent plus warfarin (Group II)
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Warfarin therapy
Number of subjects: 447

Group type: COMPARATOR
Intervention: CHADS2 score comparison
Number of subjects: 447
Study: 21480316

Group type: EXPERIMENTAL
Intervention: Long-term low-dose peginterferon therapy
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Control group (no peginterferon therapy)
Number of subjects: 1050
Study: 19657203

Group type: EXPERIMENTAL
Intervention: Therapeutic touch (contact on neck and shoulders, delivered twice daily for 3 days)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo treatment (mimic treatment identical in appearance)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 65
Study: 16445337

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SW and nonsteroidal anti-inflammatory drugs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 15789920

Group type: COMPARATOR
Intervention: Antithyroid drugs
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs + Azathioprine
Number of subjects: 64
Study: 11331684

Group type: EXPERIMENTAL
Intervention: Contingent TV (pedaling a stationary cycle ergometer)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no contingent TV)
Number of subjects: 10
Study: 9250136

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN1 to AN6 phases)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN1 and AN2 phases)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN3 and AN4 phases)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN5 and AN6 phases)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (all phases)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa patients (AN4, AN5, and AN6 phases)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 7506400

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation treatment
Number of subjects: 271

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 271
Study: 30122772

Group type: EXPERIMENTAL
Intervention: Alternating rapid palatal expansion and constriction (RPE/C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rapid palatal expansion (RPE)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RPE/C
Number of subjects: 36
Study: 28818095

Group type: EXPERIMENTAL
Intervention: Pegloticase every 2 weeks (Q2w)
Number of subjects: 1695

Group type: EXPERIMENTAL
Intervention: Pegloticase every 4 weeks (Q4w)
Number of subjects: 1695

Group type: COMPARATOR
Intervention: NIAID/FAAN criteria for anaphylaxis
Number of subjects: 1695
Study: 26630989

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (at least 30 min for five times per week)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Controlled group (exercise not mandatorily required)
Number of subjects: 120
Study: 23884073

Group type: EXPERIMENTAL
Intervention: Psychoeducation (PE) sessions
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard treatment (pegylated interferon alfa‐2a and ribavirin therapy) without psychoeducation
Number of subjects: 198
Study: 22030226

Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD)
Number of subjects: 40
Study: 18427001

Group type: EXPERIMENTAL
Intervention: p53 expression
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bcl-xL expression
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Risk groups based on p53 and Bcl-xL expression
Number of subjects: 45
Study: 16540603

Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 12859445

Group type: EXPERIMENTAL
Intervention: UGRP1‐112G/A polymorphism
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Presence of at least one A allele in genotype
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: ‐112A allele prevalence
Number of subjects: 131
Study: 12505968

Group type: EXPERIMENTAL
Intervention: Sleeved bronchoscope
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonsleeved bronchoscope
Number of subjects: 50
Study: 10791186

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline 2 cc i.v. (Control)
Number of subjects: 20
Study: 9715298

Group type: EXPERIMENTAL
Intervention: Intrathecal pethidine 5% (50 mg/ml) 0.5 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5% lignocaine 1 ml
Number of subjects: 100
Study: 1864086

Group type: COMPARATOR
Intervention: Topical prednisolone eye drops (tapering dosage)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral acyclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study: 6824996

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) at doses of 0.1 mg, 0.5 mg, and 1.0 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (140 mM hydrochloric acid)
Number of subjects: 6
Study: 30229406

Group type: EXPERIMENTAL
Intervention: Nonfluoroscopic catheter visualization (NFCV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Established mapping systems and fluoroscopy as needed (CONV group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: NFCV
Number of subjects: 80
Study: 29540181

Group type: EXPERIMENTAL
Intervention: Social media intervention group (SM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no social media intervention)
Number of subjects: 37
Study: 26787469

Group type: EXPERIMENTAL
Intervention: Mobile health supported physical activity intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (physical activity advice booklet only)
Number of subjects: 68
Study: 24588936

Group type: EXPERIMENTAL
Intervention: Pegloticase
Number of subjects: 169
Study: 22334085

Group type: EXPERIMENTAL
Intervention: Oily emulsion of DHA-phospholipids containing melatonin and tryptophan
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20497747

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 0
Study: 17945530

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg qd)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg qd)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16230121

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin (3 x 5000 IU/day for 2 days, then 2 x 5000 IU/day for 12 days, maintenance 5000 IU/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral pentosan polysulfate (PPS) alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin and oral PPS
Number of subjects: 41
Study: 11850096

Group type: EXPERIMENTAL
Intervention: Insulin treatment for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Insulin treatment for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral agents (comparison group)
Number of subjects: 30
Study: 9859881

Group type: EXPERIMENTAL
Intervention: Intensive smooth speech
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent-home smooth speech
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive electromyography feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreatment
Number of subjects: 0
Study: 7625338

Group type: EXPERIMENTAL
Intervention: Low fat diet (LF) - 20% of energy as fat, 67% as carbohydrate, 13% as protein; 4.80 kJ/g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Medium fat diet (MF) - 40% of energy as fat, 47% as carbohydrate, 13% as protein; 5.59 kJ/g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High fat diet (HF) - 60% of energy as fat, 27% as carbohydrate, 13% as protein; 7.04 kJ/g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carbohydrate balance
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fat balance
Number of subjects: 6
Study: 2199131

Group type: EXPERIMENTAL
Intervention: 20 mg (+/‐)‐nicardipine
Number of subjects: 79

Group type: COMPARATOR
Intervention: 10 mg nifedipine
Number of subjects: 79
Study: 150813

Group type: EXPERIMENTAL
Intervention: Zinc sulfate monohydrate, 411 mg total daily dosage
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 22
Study: 29242413

Group type: EXPERIMENTAL
Intervention: Daily assisted physical exercise (one session daily starting from one week of postnatal age, including range-of-motion exercises with gentle compression, flexion and extension of all extremities for 10-15 min)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care (Control group, no massage or exercise)
Number of subjects: 50
Study: 28256333

Group type: EXPERIMENTAL
Intervention: Tight Control (GI)
Number of subjects: 40
Study: 26125277

Group type: EXPERIMENTAL
Intervention: Pregabalin (n=47)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Sertraline (n=60)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 107
Study: 23102845

Group type: EXPERIMENTAL
Intervention: 100 mg FSH im once a day for 4 days (N = 5)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 200 mg FSH sc on Day 3 and Day 5 (N = 4)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 200 mg FSH plus 2.5 mg LH sc on Day 3 and Day 5 (N = 4)
Number of subjects: 13
Study: 22003109

Group type: EXPERIMENTAL
Intervention: Computerized acuity mean measurement (CAMM6)
Number of subjects: 100

Group type: COMPARATOR
Intervention: ETDRS chart
Number of subjects: 100

Group type: COMPARATOR
Intervention: ETDRS measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CAMM6 measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CAMM6
Number of subjects: 100
Study: 18433659

Group type: EXPERIMENTAL
Intervention: Physical restraints applied during the first 2 hours of admission
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Intense agitation
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Extreme agitation
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Substance misuse
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Diagnoses other than psychosis
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Time of admission in the morning
Number of subjects: 301
Study: 16501860

Group type: EXPERIMENTAL
Intervention: Low-dose gemcitabine infusion (250 mg/m2)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard-dose gemcitabine infusion (1000 mg/m2)
Number of subjects: 25
Study: 12928902

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times/day for 3 weeks (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times/day for 1 year (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times/day in combination with MMF 1 g twice daily for 1 year (Group C)
Number of subjects: 30
Study: 11164664

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.1 mg/kg injected subcutaneously three times a week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Isotonic saline solution injected at the same times as GH
Number of subjects: 20
Study: 9217519

Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Combination of lorazepam and haloperidol
Number of subjects: 98
Study: 7951573

Group type: EXPERIMENTAL
Intervention: Thyroglobulin (Tg) concentration in cyst fluid
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Lactic dehydrogenase (LDH) isozyme patterns in cyst fluid
Number of subjects: 125
Study: 2823840

Group type: EXPERIMENTAL
Intervention: 1500 aPTT‐U low molecular weight heparin plus 0.5 mg dihydroergotamine (HNMD; Embolex NM)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 5000 IU of the heparin‐dihydroergotamine combination Heparin‐Dihydergot (twice daily)
Number of subjects: 160
Study: 2278166

Group type: EXPERIMENTAL
Intervention: Captopril (n = 17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Enalapril (n = 16)
Number of subjects: 33
Study: 49984

Group type: EXPERIMENTAL
Intervention: Chemotherapy (Hydroxyurea) only
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Radiotherapy only
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy and radiotherapy
Number of subjects: 234

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 234
Study: 31811737

Group type: EXPERIMENTAL
Intervention: WeChat-based 'Three Good Things' intervention
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 73
Study: 30983166

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg daily
Number of subjects: 3002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3002
Study: 28902426

Group type: EXPERIMENTAL
Intervention: Surgical therapy aiming at pocket elimination with systemic antibiotics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Surgical therapy aiming at pocket elimination with antiseptic agent for implant surface decontamination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Surgical therapy aiming at pocket elimination with both systemic antibiotics and antiseptic agent
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgical therapy aiming at pocket elimination (control group)
Number of subjects: 100
Study: 26323937

Group type: EXPERIMENTAL
Intervention: Benznidazole
Number of subjects: 2854

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2854
Study: 23541376

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure <140 mm Hg
Number of subjects: 10705

Group type: COMPARATOR
Intervention: Systolic blood pressure ≥140 mm Hg
Number of subjects: 10705

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure <120 mm Hg
Number of subjects: 10705
Study: 21366634

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for 2 weeks)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 1558
Study: 18853180

Group type: EXPERIMENTAL
Intervention: Fluid replacement at 66% (HI)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fluid replacement at 0% (LO)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fluid replacement at 33% (LO)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fluid replacement at 100% (HI)
Number of subjects: 6
Study: 17448975

Group type: EXPERIMENTAL
Intervention: Reversed saphenous vein
Number of subjects: 85

Group type: COMPARATOR
Intervention: Collagen impregnated woven polyester prosthesis
Number of subjects: 85
Study: 12970274

Group type: EXPERIMENTAL
Intervention: GH at 25.0 microg/kg x day (pediatric dose)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: GH at 12.5 microg/kg x day (adult dose)
Number of subjects: 149

Group type: COMPARATOR
Intervention: No GH treatment (control)
Number of subjects: 149
Study: 10784079

Group type: EXPERIMENTAL
Intervention: Parent training only
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Full-day treatment classroom only
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Combination of parent training with classroom treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 158
Study: 8678501

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of azasetron (2.5 mg bolus followed by 7.5 mg continuous infusion for 24 hrs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of azasetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bolus intravenous injection of azasetron (10 mg)
Number of subjects: 0
Study: 2059393

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/day for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 to 40 mg/day for 8 weeks (after enalapril)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nitrendipine for 8 weeks (first group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril after nitrendipine for 8 weeks (second group)
Number of subjects: 24
Study: 6132354

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 60
Study: 31036114

Group type: EXPERIMENTAL
Intervention: Fat harvested from medial thigh (Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fat harvested from abdomen (Group B)
Number of subjects: 39
Study: 28335701

Group type: EXPERIMENTAL
Intervention: Whole-body vibration therapy (VG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy (CG)
Number of subjects: 30
Study: 26043560

Group type: EXPERIMENTAL
Intervention: Tiaogan Lipi Recipe (TLR), one dose per day for 12 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo, one dose per day for 12 weeks
Number of subjects: 99
Study: 23690237

Group type: EXPERIMENTAL
Intervention: Intensive patient/intensive physician
Number of subjects: 275

Group type: COMPARATOR
Intervention: Minimal physician intervention
Number of subjects: 275

Group type: COMPARATOR
Intervention: Minimal patient/minimal physician
Number of subjects: 275

Group type: COMPARATOR
Intervention: Minimal patient/intensive physician
Number of subjects: 275

Group type: COMPARATOR
Intervention: Intensive patient/minimal physician
Number of subjects: 275
Study: 21593661

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg twice daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Efavirenz (EFV) 600 mg once daily
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 57
Study: 18501900

Group type: EXPERIMENTAL
Intervention: Cetrorelix protocol
Number of subjects: 564

Group type: COMPARATOR
Intervention: Long protocol
Number of subjects: 564
Study: 16945057

Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention including academic detailing, provider-specific data, educational materials for providers, and motivational materials for patients
Number of subjects: 10696

Group type: EXPERIMENTAL
Intervention: Patients whose blood pressure was controlled at baseline
Number of subjects: 10696

Group type: EXPERIMENTAL
Intervention: Patients whose blood pressure was not controlled at baseline
Number of subjects: 10696

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 10696